MDT-BRIDGE (NCT05925530) is AstraZeneca's phase II adaptive study in resectable and borderline-resectable stage IIB–IIIB NSCLC: 1–2 cycles of neoadjuvant durvalumab plus chemotherapy, then multidisciplinary reassessment routes each patient to surgery or definitive chemoradiotherapy, followed by adjuvant or consolidation durvalumab. Presented at WCLC 2026 (OA04.02, Martin Reck): 74.6% overall resection rate, 96.2% R0, pCR 27.3%, and 12-month EFS of 90.1% in the resectable cohort.
Adaptive phase II: 1–2 cycles of neoadjuvant durvalumab + platinum chemotherapy, then MDT reassessment — surgery if resectable, definitive chemoradiotherapy if not — followed by adjuvant durvalumab (post-surgery) or consolidation durvalumab (post-CRT). (Presented WCLC 2026 OA04.02; verbatim KOL captures)
Of 142 treated patients (full analysis set): 74.6% underwent resection, and 96.2% OF THOSE RESECTED achieved R0; pCR 27.3% (full analysis set); 12-month EFS 90.1% among patients deemed resectable at MDT reassessment; 92.3% of all patients received curative-intent surgery or CRT; 76% of borderline-resectable patients converted to resectable. (Presented data via the verbatim physician captures on this page: Patil, Özkerim, Horinouchi, Díaz-García)
Resectability becomes a treatment-modifiable state assessed after induction rather than a fixed baseline call — the study's core concept per the physicians discussing it. (Verbatim KOL posts)
⚠️ The MDT-BRIDGE strategy is investigational. Durvalumab (Imfinzi) is approved in other NSCLC settings (unresectable stage III consolidation per PACIFIC; perioperative per AEGEAN); this bridging paradigm is not an approved regimen. (FDA labeling context)
Perioperative morbidity and treatment-related adverse-event data from OA04.02 are NOT reproduced on this page — our coverage reports the presented efficacy and surgical outcomes only. Consult the primary presentation for the safety tables before drawing risk-benefit conclusions. (Editorial disclosure)
Urs Weber: “I really like the adaptive design of MDT-Bridge.” Yago Garitaonaindía: “Compelling results” — “Stop calling full resectability upfront: assess it after neoadjuvant chemo-IO, when the tumour has already shown you what it does.”
🔥 Outstanding piece of work published today in Nature Medicine! Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏 The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy? This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients. Congratulations to everyone involved! 👏 🔗 https://t.co/ZSkztTwXDK Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors #ESMO26 #NatureMedicine #LungCancer #NSCLC #ThoracicOncology #Immunotherapy #ClinicalResearch #MultidisciplinaryCare #CancerResearch
I've been reflecting on the recently published MDT-BRIDGE study and what its results tell us about the importance of multidisciplinary treatment decisions for patients with resectable NSCLC. As a radiation oncologist who has long believed that chemoradiotherapy (CRT) can achieve outcomes comparable to surgery in selected patients with low-volume stage II–III NSCLC, I see an important message in the recent publication. https://t.co/Lj1g5X8qT5 MDT-BRIDGE enrolled 142 operable patients with stage IIB–IIIB NSCLC, including 92 classified as resectable and 50 as borderline resectable. All were technically resectable, yet the borderline group was deemed more challenging to resect. Importantly, radiation oncologists participated in multidisciplinary team (MDT) assessments both before treatment and after two cycles of neoadjuvant chemoimmunotherapy. This distinguishes MDT-BRIDGE from the treatment-selection pathways commonly associated with phase III neoadjuvant chemoimmunotherapy trials, in which medical oncologists and thoracic surgeons generally drove decisions about systemic therapy followed by resection. Such an approach has been associated with 20% of patients not undergoing planned surgery, with RWE studies reporting even higher surgery-aborted rates, exceeding 40%. This begs the question of whether earlier radiation oncologist involvement can reduce the number of patients who ultimately receive no surgery or curative-intent local therapy. The MDT-BRIDGE results offer an encouraging signal. Of the 142 patients who began neoadjuvant tx: - 106 (74.6%) proceeded to surgery - 25 (17.6%) received CRT instead - Only 11 (7.7%) received neither Remarkably, all 25 patients redirected to CRT completed their treatment, and 23 (92%) subsequently initiated consolidation durvalumab. Thus, 92.3% of patients received curative-intent local therapy, despite more than one-third initially being classified as borderline resectable. These findings highlight the potential value of an MDT that includes a radiation oncologist empowered to reassess the original surgical plan and redirect patients to CRT when resection is no longer feasible or appropriate. Notably, the resulting 7.7% rate of patients receiving no local therapy was substantially lower than the approximately 20% surgical attrition rates reported in prior phase III neoadjuvant trials enrolling similar patients. Of course, MDT-BRIDGE was a single-arm phase II study, and its results do not establish the impact of radiation oncologist participation on the relatively low rate of local therapy attrition. Nevertheless, the findings raise an important hypothesis worthy of further study. Especially, since previous studies for stage I NSCLC have demonstrated better surgical outcomes at institutions offering both surgery and SBRT, suggesting that access to alternative local therapies may improve patient selection and outMA takeawaycomes. https://t.co/iD8HZNAuDn https://t.co/SzC08F6hIR My updated takeaway from MDT-BRIDGE is that a radiation oncologist's value in the MDT extends well beyond delivering radiotherapy. It includes helping colleagues and patients navigate treatment decisions, reassessing the feasibility of competing approaches, and preserving opportunities for cure when the original plan changes. Even when surgery is the preferred initial strategy. I've seen this work incredibly well at my institution, and hope it's how all resectable pts are managed worldwide. For those interested in exploring the broader evidence supporting the value of MDT cancer care, I recommend this excellent review, published in 2024:
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥MDT-BRIDGE: ctDNA Clearance (CL) During Neoadjuvant Treatment (Neoadj Tx) and Its Association With Outcomes in Patients (Pts) With Resectable/Borderline Resectable Stage IIB–IIIB NSCLC 🎙️ @DoctorJSpicer 🔢LBA62 🎯ctDNA CL at C2D1 Had 83.3% PPV for pCR 🎯Pre-Surgery CL: pCR 76.0% vs Non-pCR 20.9% 🎯No EFS Events in Resected Pts With CL vs 12-Mo EFS 88.9% Without CL (n=107) ☑️NCT05925530 🔗 https://t.co/a1n3LKVbtq @OncoAlert @Larvol @myESMO @IASLC
🔥MDT-BRIDGE: Neoadjuvant durvalumab + chemo in resectable/borderline resectable NSCLC — MDT-guided adaptive approach 🆙 @NatureMedicine #ESMO26 🎯ctDNA CL at C2D1 Had 83.3% PPV for pCR 🎯Pre-Surgery CL: pCR 76.0% vs Non-pCR 20.9% 🎯No EFS Events in Resected Pts With CL vs 12-Mo EFS 88.9% Without CL (n=107) 🎙 @MartinReck2 @DoctorJSpicer ☑️NCT05925530 #LCSM @OncoAlert @Larvol @myESMO @IASLC
Proud participation of our hospital 🏥 in the MDT-BRIDGE leading by @rosaalvarezal with a terrific publication. Congrats!!!! #ESMO26 #LCSM
Congrats to Reck, Spicer, Filippi and team on the full MDT-BRIDGE paper in Nature Medicine! Really appreciate seeing the RT protocol and full denominators alongside the ASTRO results. 👏 This single-arm ph2 enrolled 142 pts with resectable or borderline-resectable stage IIB-selected IIIB, EGFR/ALK-wt NSCLC. Durvalumab + platinum chemo x2c→ MDT reassessment→ additional chemoimmunotherapy and surgery, or CRT, followed by durvalumab. Resection was 74.6% (95CI 66.7-81.6), with R0 in 96.2% of those who started surgery. pCR was 27.3% in the resectable analysis cohort. The 12-mo EFS estimates are 88.5% overall and 90.1% in that resectable cohort. Different denominators, same readout. The RT protocol details are useful: nominal 60/30 (60 Gy ±10% in 2 Gy fx), 5 fx/wk for ~6 wk, concurrent or sequential platinum chemo. SBRT was not allowed. IMRT with daily CBCT was preferred, then consolidation durvalumab q4w up to 12c. All 25 pts who started CRT completed it: 21 concurrent, 4 sequential. 23 received consolidation durvalumab. The post hoc CRT-treated analysis estimated 12-mo PFS at 85% (95CI 59.8-95.0), measured from the FIRST study-treatment dose, including induction. CRT-period G3/4 AEs were 28%; pneumonitis 8% (2 pts, both G2). During consolidation, G3/4 AEs were 17.4%, AE discontinuation 13%, and pneumonitis 8.7% (G1/2). One cardiac-failure AE death occurred during consolidation; the paper reports no treatment-related AE deaths in that period. The safety windows extend beyond treatment delivery and can overlap. The ESMO ctDNA analysis adds an interesting association. Pre-Sx/CRT clearance occurred in 33/90 evaluable pts (36.7%). C2D1 clearance had an 83.3% PPV for pCR (95CI 43.6-99.1). Among resected pts, no EFS events occurred with pre-Sx clearance (n=28); 12-mo EFS without clearance was 88.9% (n=40). In CRT-treated pts, 12-mo PFS was 100% with pre-CRT clearance vs 77.5% without. The paper now supplies those subgroup sizes: just 4 vs 16 pts, with 2 vs 6 at risk at 12 mo. One later event occurred in the clearance group, so 100% is a timepoint estimate, not no events throughout follow-up. Useful prospective evidence that patients can reach definitive CRT after starting on a surgical pathway. The unanswered question remains who benefits from that sequence versus going directly to CRT or selecting for NAC-ICO with intent for organ preservation. Selected cohorts, immature EFS/PFS and no reported OS cannot settle that, and ctDNA does not yet tell us which local therapy to choose or omit. https://t.co/he6OT4TsJ5 https://t.co/LaiIFjAdII #radonc #ESMO26 #LCSM
Compelling results from MDT-BRIDGE #WCLC26 Two personal takeaways/ideas Stop calling full resectability upfront: assess it after neoadjuvant chemo-IO, when the tumour has already shown you what it does. ➕ the value is in the sequence, not just the drug. Prime with IO, let the immune response settle, then irradiate. Personal opinion: it will hold in upfront unresectable disease too (APOLO). 👇👇👇
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resectable NSCLC received 1-2 cycles of durvalumab + chemotherapy then surgery if resectable or CRT if not, followed by adjuvant/consolidation durvalumab. Of those with borderline resectable NSCLC, 62% underwent resection (97% R0). Overall resection rate 75% and 27% pCR rate.

🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗 https://t.co/rN1vqVmvgD @OncoAlert @Larvol @IASLC

#WCLC26 | MDT-BRIDGE Neoadjuvant durvalumab + platinum-based chemotherapy in resectable/borderline resectable stage IIB–IIIB NSCLC: • Resection rate: 74.6% • pCR: 27.3% • 12-month EFS: 90.1% in the resectable cohort • 92.3% of patients underwent either surgery or CRT after neoadjuvant treatment. An interesting MDT-based approach integrating surgery and CRT according to reassessment @OncoAlert @ManuelDomine @weoncologists @OpenMedKate

MDT-BRIDGE: Treat First. Decide Surgery Later? A simple but interesting concept in locally advanced NSCLC: • Start with chemo-immunotherapy rather than locking in the local treatment upfront. • Then reassess in the MDT. • If resectable → surgery. • If not resectable → definitive chemoradiotherapy. • Continue durvalumab after either pathway. The idea: Treat → Reassess → Choose the best curative-intent path. Reference: Reck M et al. MDT-BRIDGE Primary Analysis. WCLC 2026; OA04.02. #MVOnco #WCLC2026 #MDTBRIDGE #NSCLC #LungCancer

🫁 MDT-BRIDGE: a perioperative-to-definitive strategy for stage IIB-IIIB NSCLC. @MartinReck2 Neoadjuvant durvalumab + chemotherapy followed by surgery or CRT achieved: • Resection rate: 74.6% • R0 resection: 96.2% • pCR: 27.3% • 12-month EFS: 90.1% in resectable patients • 12-month PFS: 75.1% in patients becoming unresectable Overall, 92.3% received surgery or CRT, supporting multidisciplinary reassessment to maintain curative-intent treatment. #CánCare #NSCLC #ThoracicOncology #Immunotherapy #Durvalumab #WCLC26 @IASLC

8. MDT-BRIDGE ⭐️Neoadjuvant durvalumab + chemo --> followed by serial MDT reassessment allowed 92.3% of patients to receive to curative-intent surgery or CRT, even with nearly a third of pts having borderline resectable disease 🗝️ KEY INSIGHTS: - 74.6% overall resection rate (n = 142) - 96.2% R0 resection - 27.3% pCR among patients remaining resectable - 90.1% 12-mo EFS in the resectable cohort - 75.1% 12-mo PFS in those converted to CRT ⚡️The interesting concept here isn't prior neoadjuvant exposure. Rather it’s the dynamic treatment strategy, allowing patients to transition from surgery to definitive CRT rather than abandoning curative intent when resectability changes. This will be a heavily debated study. @lcsmchat @OncoAlert @OncLive @LungCancerEu @Lung_Cancers @MedwatchHQ
Locally advanced NSCLC forces an upfront call — operable or not — that determines a patient's entire pathway. MDT-BRIDGE inverts that: give 1–2 cycles of durvalumab plus chemotherapy first, then let the multidisciplinary team decide with response information in hand. At WCLC 2026 Martin Reck presented the primary analysis: nearly three-quarters of all patients were resected (96.2% R0), three-quarters of the borderline group converted to resectable, and 92.3% reached curative-intent local therapy of one kind or the other.
Physicians called out the pragmatism: the design mirrors how tumor boards actually think, and offers a protocolized route for the borderline group that trials usually exclude. Patient selection and longer follow-up remain the open questions KOLs flagged.
Phase II adaptive: neoadjuvant durvalumab + chemo (1–2 cycles) → MDT reassessment → surgery or definitive CRT → adjuvant/consolidation durvalumab. (WCLC 2026 OA04.02 via verbatim captures)
Resectable and borderline-resectable stage IIB–IIIB NSCLC; n=142 in the presented analysis. (Verbatim KOL captures)
Resection rate, R0 rate, pCR, EFS; 12-month EFS 90.1% in the resectable cohort. (Verbatim KOL captures)
Martin Reck, MD — WCLC 2026 oral OA04.02. (Verbatim KOL captures)
Of the 142 treated patients (full analysis set), 74.6% underwent resection; the R0 rate of 96.2% is among those resected, and pCR of 27.3% is in the full analysis set. Among borderline-resectable patients, 76% converted to resectable after induction, and 92.3% of all patients received curative-intent surgery or chemoradiotherapy. Safety and perioperative-morbidity tables are in the primary presentation and are not reproduced here. (WCLC 2026 OA04.02, via verbatim physician captures: Patil, Özkerim, Díaz-García)
Resection 74.6% · R0 96.2% · pCR 27.3%12-month EFS was 90.1% in the resectable cohort (12-month PFS 75.1% reported for the definitive-CRT pathway per physician capture) — early but supportive of the bridging strategy; longer follow-up pending. (WCLC 2026 OA04.02 via verbatim captures: Horinouchi, Díaz-García)
12-mo EFS 90.1% (resectable cohort)MDT-BRIDGE (NCT05925530) is an AstraZeneca phase II study in resectable and borderline-resectable stage IIB–IIIB NSCLC. Patients receive 1–2 cycles of neoadjuvant durvalumab plus chemotherapy, then a multidisciplinary team reassesses resectability: resectable patients go to surgery, others to definitive chemoradiotherapy, with adjuvant or consolidation durvalumab afterward.
In the primary analysis presented by Martin Reck (OA04.02, 142 treated patients): a resection rate of 74.6% of all treated patients, R0 in 96.2% of those resected, pathological complete response in 27.3%, 12-month event-free survival of 90.1% among patients deemed resectable at MDT reassessment, and 92.3% of all patients reaching curative-intent surgery or CRT. About 76% of borderline-resectable patients became resectable after induction. Safety and perioperative-morbidity data are in the primary presentation and not reproduced on this page.
It treats resectability as a dynamic, treatment-modifiable state judged after induction therapy rather than a fixed baseline label — matching how multidisciplinary tumor boards actually work and creating a protocolized pathway for borderline patients whom conventional trials exclude.
No. The MDT-BRIDGE strategy is investigational. Durvalumab (Imfinzi, AstraZeneca) is approved in other NSCLC settings — consolidation after chemoradiotherapy in unresectable stage III (PACIFIC) and perioperative use (AEGEAN) — but the adaptive bridging paradigm itself is not an approved regimen.
Phase II size, no randomized comparator, and the patient-selection question physicians raised — plus the need for longer event-free and overall survival follow-up before the strategy can claim practice-changing status.
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated September 13, 2026. Every statistic carries its source label in place; every quote is verbatim from the physician's own post.